{"name":"UCB Japan Co. Ltd.","slug":"ucb-japan-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1200000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Bimzelx","genericName":"BIMEKIZUMAB","slug":"bimekizumab","revenue":1200000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":1200000000,"percentOfTotal":100,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Bimzelx","genericName":"BIMEKIZUMAB","slug":"bimekizumab","indication":"Erythrodermic psoriasis","status":"marketed","revenue":1200000000}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Levetiracetam (LEV)","genericName":"Levetiracetam (LEV)","slug":"levetiracetam-lev","indication":"Partial-onset seizures (adjunctive therapy)","status":"marketed"}]}],"pipeline":[{"name":"Bimzelx","genericName":"BIMEKIZUMAB","slug":"bimekizumab","phase":"marketed","mechanism":"Bimzelx works by binding to interleukin-17A, a protein that promotes inflammation, to reduce symptoms of psoriasis.","indications":["Erythrodermic psoriasis","Plaque psoriasis","Pustular psoriasis"],"catalyst":""},{"name":"Levetiracetam (LEV)","genericName":"Levetiracetam (LEV)","slug":"levetiracetam-lev","phase":"marketed","mechanism":"Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release.","indications":["Partial-onset seizures (adjunctive therapy)","Myoclonic seizures in juvenile myoclonic epilepsy (adjunctive therapy)","Primary generalized tonic-clonic seizures (adjunctive therapy)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFA3S0lZSThPYUVOUEdHcFU0bkdrdU4tZzdsWHFpWVBLV0FldDdmczI3OWRKVUg0Sm4yTjFaSkN4bkFudVpsdGhRUi1zUGFpZHQtdEJZMzB0SDJQUnpJckx3?oc=5","date":"2026-02-10","type":"trial","source":"Nature","summary":"Autoantibody and disease control stability following mRNA COVID-19 vaccination in rheumatoid arthritis: an observational cohort study - Nature","headline":"Autoantibody and disease control stability following mRNA COVID-19 vaccination in rheumatoid arthritis: an observational","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxNVjNqUnRFNk51aWdrMUpSWHdaQUlaclNMb09JX1FSelUxb0R0b1JFX09OU29MMzh4cEFnTnljc2tINXBMWF9aWmpvUWI3T2lOeHRPLXZwRFBHdGxBdHE2Q3JjMzVmOS1raDJDbHNZeDJOU3pQS2RzMG9uOFBza2pnUTFaOFQ4c1FodE94ME5IUDZXZmlsR2hNaTZ0eTlwQ3RnTEZON0ZTV040OVRTM0Vtb3g3US1nTkZwQ0gtbGl1c0tmdE81U1pCS2tkZi03enNQSlpJUUtnRnRuVDBmUFpiUmI2V1Ffd1pFVFJNRWtfMWF2RDhNNUd5S0pQakcyM2hfclJmNG5ueW9FUjc2TGxCS2hfQThnMmdLM3BvWWlDVFlIX2dqVnJ6OC1IUllwOFBLejdTeGdEbjNXcktENV8xdGxlSUY?oc=5","date":"2026-01-29","type":"earnings","source":"Barchart.com","summary":"Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK, UCB Pharma - Barchar","headline":"Fibromyalgia Market: Expanding Revenue Landscape to 2034 – DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Apti","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wJBVV95cUxNcEd6Rkt1MDFqcjhKb3lGcFJKT0dKOUFfcS1aOUtKTEtXMzB0Mzd3dGF1NGRlTExhMGQ4dGFVMEhFaDhLZ1RiSEpMb0VqWGZtVmFXM1ZQUHF2cnQ0UEVkT0ExeEticlFxaTA5NDZYY1BWQ3B5cWJPU2hsWjBwZGthR0plc18wNUhJNzA5enpJOTRTUURWV3pvclpwbVdJcnMxR0x4WVdmY21MQktTYTdDdFBWYmxqMkR0T2RFNEotZGc4SUxGNG9PNVRIblpvTWJJSjNGTU1xX1BQT0YxeFRSNENReGpUeTR1WDZLZm1EN2MxM2JrYlJXeHUzU3BQSFV6MVBrSEZ3MnhYLUNFVXlSLUxsUG0wMWlnVDdmcC14YUVMNjZFMmhpUWMzUjlwYWJxbTVuSF9qX215VnFPdGNpUjZHTll3MTI1UTBVNHAyVkQ0WXVpRHdnVS1tVGtUbndRU0NF?oc=5","date":"2025-12-11","type":"deal","source":"PR Newswire","summary":"Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Expansion and Advancing Global Partnership with UCB Through Acquired Rights - PR N","headline":"Lee's Pharmaceutical Holdings Limited Acquires Staccato® One Breath Technology® Platform and Assets, Driving Pipeline Ex","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNVGdFUy14RlJVa2g5UnRYamlzNTBEcHA4TmY0aHBDTXFKYWZyMVFZX19BMlhMSUFxb1F1NUtXMHJGZEhESzI1OXpNSlduQkpnNTNNSy1faUJvS1d0NHBnM2dObGFoZjVRWDJDaXdFZFJldVB1MTItOVkzSU90UHMtYU83VWVOM3ZYQ1lEdy1EekFZNExMV2JlaUxoMzVjcTBMTy04WlFEeDA2ZVZCR0VidDdkcjB1ZG83ZVRrcW9uUVFES1BnNTRDU05pQ19lN0JYOUhWaA?oc=5","date":"2025-07-31","type":"pipeline","source":"UCB","summary":"From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance - UCB","headline":"From Differentiated Innovation to Outstanding Delivery - A Strong First Half Performance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE1BZHRmMmdpQWplZlV5M2JYbTlXYW90b3NHOS1JRzc1YXFTV1pvOFlBNTRKY1dIU01IYUdOZW9JV1VqdTk1MmNyZElMSTRIUUhHNUdzdjFjbEFUNl8wYlB1X1RpanFFblc0RlE?oc=5","date":"2025-07-23","type":"pipeline","source":"Wiley Online Library","summary":"Co-Occurrence of High-Frequency Oscillations and Interictal Focal Paroxysmal Fast Activity During Scalp EEG: A Comparison With Single Spikes - Wiley Online Library","headline":"Co-Occurrence of High-Frequency Oscillations and Interictal Focal Paroxysmal Fast Activity During Scalp EEG: A Compariso","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6AFBVV95cUxNdGFZWGZLUG1iRHMyZm9Ham5KdnY1V205aVhqa1M4eHNXN1R5TEZTclpSWjRNY0hsS3VFZzl2UlM5LWdGQjd5T0wxQjZEcks5QV9ESTlBUW9xek5RNktZdzhBbTFrMzZfNmhkLURaN1JlTUV5a2ZlMTJ1cXBKeWw2Skl5Y1hBUURiTFpnQVJ0WVI1aUZtcVNSZHFYVFlLOVNFQWtyaWlwU0JhOThSNE9YTFBlQTRtQkI2V2ZuUjdhX0pBZnlYS3hNOGlmb0pWVGR1ZkhhbXJaN2lDTlowaE9hSDNVa3ZlTkM0?oc=5","date":"2025-04-11","type":"pipeline","source":"Healthcare Asia Magazine","summary":"UCB JAPAN COMPANY LTD. receives ESG Program of the Year - Japan at Healthcare Asia Pharma Awards 2025 - Healthcare Asia Magazine","headline":"UCB JAPAN COMPANY LTD. receives ESG Program of the Year - Japan at Healthcare Asia Pharma Awards 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQeUNSWE9fYUNjbWRjWlljaWp4cWdWd1A4c2hzRGt3MkhkTlVWRC0waEtKeFFhenlXVVcyY25HdVkyaDB2MTVNNVJDQ0tPSkNra2I5cmZzMjNzTlk0WWtZaTRYMjZ3RzhReUFUVmRkOVhha2NIRVhObzFHQVFCYW56dUtIanNpSnV3aThOX1BGQ1BSQ1RKbDVKQ1dERmxsYjAzYmgtSFNxTkpqcWxJ?oc=5","date":"2025-04-05","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com","headline":"Pharma 50: The top pharma companies in the world for 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQSmY5cXh2VkxFbDkwOVAwRFZfSjJ0ZE5xdzdJSXlJTVN2SUEwdnBFTjQ5c1ptMDRiSDVIWm92Z2E0YU5kNTRDemRDSmRISkoxN0NwOXhRa0dsdE9sM3NzVjF5UUZvN0NoVHkzbVRNV1ZBQ2hOY1JzQV9uVTdULU1fa202MmxCZGpKSUhvQ0pkNFpHQmlYZ3dzMUY1UWtBakRlMnhEWFgzZjczTVhmaW1YMWZXVkFCUm9fbEJHY0ZmVjlSQWZfSkJ5QlZDVQ?oc=5","date":"2025-02-27","type":"pipeline","source":"UCB","summary":"On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth - UCB","headline":"On Growth Path for a Decade plus: Strong Launch Execution driving Company Growth","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxPTEEzWTdwZG9TcW9oNzMzQVRveUJIUWI3UHFfQ3FBeWczbFN0eTNoLWM0Z3hTeVItWUFxN2NRNFNzaldKMmJvMXNjYUFvMld5T1hLdDNsYjVwTmVkaENIeHdXTlVfdjV5eVlkdjZqRVhxXzd6elBXaTZhTlVVR05ENGE5enRvYU5pcGFoUFZDTDlrNThyazJ2S1dmeTVuc2lvT3R4N2hjeW12WVEyaERoRTdWY0Q2Vl8tNVpoY0tUazZURnZ3akwxNA?oc=5","date":"2025-01-21","type":"pipeline","source":"Citeline News & Insights","summary":"The World’s Top 100 Pharma Companies: 2024 Sales Rankings - Citeline News & Insights","headline":"The World’s Top 100 Pharma Companies: 2024 Sales Rankings - Citeline News & Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQU0luNlNqM1p3WDVvaU5RZ3J5ZkFYMUZZeTl4bG92TzUwMEg3QWJnRjFCaVdtT3FaTDVFcUJuMVkwcVM0dmZuRmRlREZpRE1kYnFQMy1KU2xkQVhNYkR4cHdwb1g4QmlKY2FsZUpWb2wyTlJ6NGNNcHY2bnB5WnpUeGN3QjBoY0pHTURRVmwyZUVBR3JlTFBjNmZBUlVKaGx1ZVV4cXFQWEtmUQ?oc=5","date":"2024-08-30","type":"pipeline","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Sanofi's flu shot setback; DualityBio's IPO plan; UCB's China asset sale - Fierce Pharma","headline":"Fierce Pharma Asia—Sanofi's flu shot setback; DualityBio's IPO plan; UCB's China asset sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTE15YUdPUk9yaWVPMFJUWlJSRnB3bUFiZmZpM09XTjN0RUVOekhQV3JLQk02enYzbkgtQTc3ekxtN2Z2enlnbWVleHpqc2Z3T3FSVlp6Q2NxMC1mdUx4LTk0UlFyb2REcExzWGNRdQ?oc=5","date":"2024-03-13","type":"pipeline","source":"European Medical Journal","summary":"Pharma in Japan - European Medical Journal","headline":"Pharma in Japan","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPeWRSOGhDc0RvRjJOSXVPOXFFMmktaEZ4MXJmcWl2U1I0WkRkTTZrWU5KQ1FVOURmajc2Smw2SEpoN0U1dE5GV3BhNExJQTBINEttWEh3LWw1bEFuUHU4SWhJTld2RnY3QlB1SEZrNEpUMkluNjlLdDZ3YzZ1VTEtQ0JsTk8wa2VD?oc=5","date":"2020-07-27","type":"pipeline","source":"PR Newswire","summary":"UCB Half Year Report 2020 - PR Newswire","headline":"UCB Half Year Report 2020","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}